SB 203853
Latest Information Update: 02 Oct 1998
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 02 Oct 1998 Discontinued-Preclinical for Bacterial infections in United Kingdom (PO)
- 02 Oct 1998 Discontinued-Preclinical for Bacterial infections in USA (PO)
- 13 Mar 1997 No-Development-Reported for Bacterial infections in United Kingdom (PO)